Advertisement
Canada markets close in 30 minutes

  • S&P/TSX

    21,978.38
    +93.00 (+0.42%)
     

  • S&P 500

    5,111.72
    +63.30 (+1.25%)
     

  • DOW

    38,302.92
    +217.12 (+0.57%)
     

  • CAD/USD

    0.7319
    -0.0004 (-0.05%)
     

  • CRUDE OIL

    83.73
    +0.16 (+0.19%)
     

  • Bitcoin CAD

    87,330.07
    -1,050.82 (-1.19%)
     

  • CMC Crypto 200

    1,332.79
    -63.74 (-4.56%)
     

  • GOLD FUTURES

    2,349.40
    +6.90 (+0.29%)
     

  • RUSSELL 2000

    2,003.21
    +22.09 (+1.12%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • NASDAQ

    15,962.53
    +350.77 (+2.25%)
     

  • VOLATILITY

    14.98
    -0.39 (-2.54%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6837
    +0.0016 (+0.23%)
     
MARKETS LIVE BLOG:

STOCKS RISE, LED BY STELLAR ALPHABET, MICROSOFT EARNINGS

Latest stubborn U.S. inflation reading will bring about more 'wait and see' from the Fed

Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Sona Nanotech Inc. (SNANF) Investigation

ACCESSWIRE
·2 min read

NEW YORK, NY / ACCESSWIRE / November 27, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sona Nanotech Inc. ("Sona" or "the Company") (OTCQB:SNANF). Investors who purchased Sona securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/snanf.

The investigation concerns whether Sona and certain of its officers and/or directors have violated federal securities laws.

On October 29, 2020, Sona announced that the Food and Drug Administration ("FDA") denied its request for an emergency use authorization for the marketing of its rapid COVID-19 antigen test in the United States. Following this news, Sona stock dropped 48%, and closed at $3.00 per share that same day. Then on November 25, 2020, Sona revealed its withdrawal of "an Interim Order authorization from Health Canada for the marketing of its rapid, COVID-19 antigen test in order to obtain more clinical data to augment its submission." Following this news, Sona stock dropped over 67% to close at $0.74 per share that same day.

If you are aware of any facts relating to this investigation, or purchased Sona shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/snanf. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

ADVERTISEMENT

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/618540/Bronstein-Gewirtz-Grossman-LLC-Notifies-Investors-of-Sona-Nanotech-Inc-SNANF-Investigation